Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (EMBER-3)
A recent paper by Komal Jhaveri, Clinical Director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center, published in The New England Journal of Medicine was mentioned by Yakup Ergün, Medical Oncologist at Bower Hospital, on X:
“Imlunestrant with or without Abemaciclib in Advanced Breast Cancer (EMBER-3).
Imlunestrant improves PFS in patients with ESR1 mutations. Its combination with abemaciclib extends PFS regardless of ESR1 status.”
“Imlunestrant with or without Abemaciclib in Advanced Breast Cancer”
Authors: Komal Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Lillian Smyth, François-Clément Bidard et al.
More posts featuring Yakup Ergün.
Dr. Komal Jhaveri holds the Patricia and James Cayne Chair for Junior Faculty and serves as an Associate Member in the Breast Medicine Service and Early Drug Development at Memorial Sloan Kettering Cancer Center.
As Section Head of the Endocrine Therapy Research Program and Clinical Director of the Early Drug Development Service, Dr. Jhaveri focuses on innovative approaches for breast cancer treatment, particularly in early-phase clinical trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023